

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number  
**WO 01/14365 A1**

(51) International Patent Classification<sup>7</sup>: C07D 321/00,  
A61K 31/335

David, M. [US/US]; 2817 32nd Avenue South, Seattle,  
WA 98144 (US). SIMON, Julian, A. [US/US]; 5300 S.  
Hudson, Seattle, WA 98118 (US). TZUNG, Shie-Pon  
[CN/US]; 23808 SE 44th Ct., Issaquah, WA 98029 (US).

(21) International Application Number: PCT/US00/22891

(22) International Filing Date: 18 August 2000 (18.08.2000)

(74) Agents: SANDBAKEN, Mark, G. et al.; Townsend and  
Townsend and Crew LLP, Two Embarcadero Center, 8th  
Floor, San Francisco, CA 94111-3834 (US).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AU, CA, JP, US.

(30) Priority Data:  
60/149,968 20 August 1999 (20.08.1999) US

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

(71) Applicant (*for all designated States except US*): FRED  
HUTCHINSON CANCER RESEARCH CENTER  
[US/US]; 1100 Fairview Avenue N., M/S: C2M 027,  
Seattle, WA 98109-1024 (US).

Published:  
— *With international search report.*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HOCKENBERY,

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING bcl-2 FAMILY MEMBER PROTEINS

(57) Abstract: The present invention provides agents and compositions for modulating the apoptotic state of a cell. The agents comprise derivatives of antimycins which bind to an anti-apoptotic Bcl-2 family member protein. Further, the agents preferentially induce apoptosis in cells that over-express anti-apoptotic Bcl-2 family member proteins and typically exhibit reduced binding affinity for cytochrome B. Pharmaceutical uses of the agents and compositions include treating apoptosis-associated disease, such as neoplasia and drug resistance, are also disclosed.

WO 01/14365 A1